Clinical Trials Browser

Interventional × efatutazone × Tumor-Agnostic × Clear all

NCT00408434 2020-10-19

Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer

Phase 1 Completed

32 enrolled 17 charts

Neoplasms